Cost-effectiveness of felodipine-metoprolol (Logimax) and enalapril in the treatment of hypertension.
We present results from a Swedish retrospective cost-effectiveness analysis of felodipine-metoprolol (Logimax) and enalapril in hypertension.
In the 8-week trial, the average reduction of diastolic blood pressure (DBP) and the share of patients reaching target DBP were both significantly greater in the felodipine-metoprolol group.
Cost of treatment (costs of drugs and physician visits) was somewhat higher in the felodipine-metoprolol group.
After 8 weeks, an extra 4.8 mmHg reduction and an additional 22% of patients reaching target DBP were achieved with felodipine-metoprolol at the extra cost of SEK 19 (Swedish kronor, $US 1=SEK 7.90).
The incremental cost per mmHg reduction and per patient reaching target DBP was calculated at SEK 4 and SEK 86, respectively.
Average cost-effectiveness ratios showed that the costs per mmHg reduction and per patient reaching target DBP after 8 weeks were 40 and 34% lower in the felodipine-metoprolol group, respectively.
In conclusion, felodipine-metoprolol is cost-effective in the treatment of hypertension.
Mots-clés Pascal : Hypertension artérielle, Félodipine, Antagoniste calcium, Métoprolol, Bloquant bêta-adrénergique, Enalapril, Peptidyl-dipeptidase A, Peptidyl-dipeptidases, Peptidases, Hydrolases, Enzyme, Inhibiteur enzyme, Analyse coût efficacité, Economie santé, Chimiothérapie, Traitement, Efficacité traitement, Association médicamenteuse, Homme, Etude comparative, Pression diastolique, Dihydropyridine dérivé, Antihypertenseur, Appareil circulatoire pathologie, Angiotensin converting enzyme
Mots-clés Pascal anglais : Hypertension, Felodipine, Calcium antagonist, Metoprolol, Beta blocking agent, Enalapril, Peptidyl-dipeptidase A, Peptidyl-dipeptidases, Peptidases, Hydrolases, Enzyme, Enzyme inhibitor, Cost efficiency analysis, Health economy, Chemotherapy, Treatment, Treatment efficiency, Drug combination, Human, Comparative study, Diastolic pressure, Dihydropyridine derivatives, Antihypertensive agent, Cardiovascular disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 98-0532621
Code Inist : 002B02F05. Création : 23/03/1999.